

The NCRI adjuvant breast cancer (ABC) trial

Submission date 06/04/2000	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 06/04/2000	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 07/05/2013	Condition category Cancer	☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Ms Judith Bliss

Contact details

Section of Epidemiology
The Institute of Cancer Research
15 Cotswold Road
Sutton
United Kingdom
SM2 5NG
+44 (0)20 8722 4040
abc-icrctsu@icr.ac.uk

Additional identifiers

ClinicalTrials.gov (NCT)

NCT00002582

Protocol serial number

G9437812

Study information

Scientific Title

Acronym

ABC

Study objectives

To determine the value of adding cytotoxic chemotherapy and/or (in premenopausal women) ovarian suppression to prolonged tamoxifen in women with early breast cancer.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Breast cancer

Interventions

Cytotoxic chemotherapy and/or (in premenopausal women) ovarian suppression and prolonged tamoxifen/tamoxifen

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

The main endpoint used for evaluation of treatment efficacy will be overall survival based on all cause mortality. Relapse-free survival, breast cancer mortality and cardiovascular mortality will also be compared. In a subset of patients there will be a detailed assessment of quality of life. Health economic consequences will also be determined. Ongoing biological predictors of therapeutic response studies, funded by CRUK and BCC.

Key secondary outcome(s)

Not provided at time of registration

Completion date

30/09/2005

Eligibility

Key inclusion criteria

All women with early invasive breast cancer requiring adjuvant systemic therapy are eligible for the trial providing they have:

1. Early (operable) breast cancer
2. Histological confirmation of invasive carcinoma
3. No previous malignancy (except carcinoma in situ [CIS] cervix or basal cell carcinoma)
4. Received no previous systemic treatment for their disease
5. Given consent and available for subsequent follow-up

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Female

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1993

Date of final enrolment

30/09/2005

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre**Section of Epidemiology**

Sutton

United Kingdom

SM2 5NG

Sponsor information

Organisation

Institute of Cancer Research (UK)

ROR

<https://ror.org/043jzw605>

Funder(s)

Funder type

Research council

Funder Name

Medical Research Council (UK)

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	04/04/2007		Yes	No
Results article	results	14/03/2012		Yes	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes